Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-T in advanced solid tumors
NCT05798546Phase 1Unknown
- Sponsor
- BGI
- Start
- Sep 2022
- Primary completion
- Sep 2023
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Neo-T in solid tumor, melanoma and non-small cell lung cancer (NSCLC), sponsored by BGI. Primary endpoint: Number of participants with adverse events at 1 month. Status: unknown.
02
Drugs
Neo-T
03
Conditions
solid tumormelanomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05798546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05798546.